TL;DR: The Centers for Medicare & Medicaid Services modified NCD 143, its transfer factor for multiple sclerosis coverage policy, effective March 7, 2026. Transfer factor remains non-covered for MS treatment under Medicare. Here's what billing teams need to do.
This update to NCD 143 in the CMS system reaffirms a longstanding non-coverage position. The policy classifies transfer factor — a dialysate of an extract from sensitized leukocytes — as experimental when used to treat multiple sclerosis. No specific CPT or HCPCS codes are listed in this policy. Claims submitted for this treatment under Medicare will not be covered.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Transfer Factor for Treatment of Multiple Sclerosis |
| Policy Code | NCD 143 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Low — confirms existing non-coverage, but denial risk is real if claims are submitted |
| Specialties Affected | Neurology, Immunology, Infusion Therapy |
| Key Action | Flag any transfer factor claims for MS before March 7, 2026 and confirm they are not being submitted to Medicare |
CMS Transfer Factor Multiple Sclerosis Coverage Criteria and Medical Necessity Requirements 2026
NCD 143 is the National Coverage Determination governing the Centers for Medicare & Medicaid Services' position on transfer factor as a treatment for multiple sclerosis. The policy is straightforward and leaves no room for interpretation: Medicare does not cover transfer factor for MS treatment.
The CMS transfer factor coverage policy defines transfer factor as "the dialysate of an extract from sensitized leukocytes which increases cellular immune activity in the recipient." That's the clinical basis for its use — it's an immunological agent. The problem, according to CMS, is that its use for multiple sclerosis is still experimental. That designation alone is enough to trigger denial.
Medical necessity doesn't apply here in the conventional sense. Typically, medical necessity determinations weigh clinical criteria, documentation requirements, and diagnosis codes. In this case, the question never gets that far. CMS has made a categorical coverage determination: the treatment is experimental for this indication, and Medicare won't pay for it regardless of clinical justification. Prior authorization won't help you here either — there's no prior authorization pathway for a service CMS considers experimental.
If your billing team is asking whether there's any scenario where transfer factor billing for MS gets reimbursement under Medicare, the answer this policy gives is no.
CMS Transfer Factor Exclusions and Non-Covered Indications
This entire policy is an exclusion. CMS doesn't cover transfer factor for MS treatment, period.
The word "experimental" carries specific weight in Medicare policy. When CMS labels a treatment experimental under an NCD, it's not the same as a local coverage determination where a Medicare Administrative Contractor might apply regional discretion. An NCD applies nationally. Every MAC follows it. There's no local carve-out, no coverage for specific patient populations, and no clinical exception process documented in this policy.
The real issue here is that "experimental" status in an NCD doesn't expire automatically. CMS has to actively revisit and modify a policy to change that designation. This 2026 modification to NCD 143 didn't change the coverage position — it reaffirmed it. That tells you CMS reviewed this and decided the evidence still doesn't support coverage.
If your practice or infusion center has been submitting transfer factor claims for MS patients under Medicare, those claims are being denied. That's not a documentation problem. That's a coverage problem, and documentation won't fix it.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Transfer factor for treatment of multiple sclerosis | Not Covered — Experimental | No specific codes listed in NCD 143 | Applies nationally under all MACs; no prior authorization pathway; experimental designation applies regardless of clinical documentation |
CMS Transfer Factor Billing Guidelines and Action Items 2026
The March 7, 2026 effective date for this NCD modification is your trigger to audit current billing workflows. Even though this policy reaffirms existing non-coverage rather than introducing new restrictions, modifications to NCDs are an audit flag. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture immediately. Pull any claims submitted to Medicare in the last 12 months that relate to transfer factor administration for MS patients. If any got through without denial, document that and flag it for your compliance officer. Claim denial rates for non-covered services affect your payer relationships and your compliance posture. |
| 2 | Update your coverage policy reference documents before March 7, 2026. Your billing team's internal payer policy library should reflect NCD 143 as modified. Mark transfer factor for MS as non-covered under Medicare with no clinical exceptions. Make sure your charge capture system can't route these claims to Medicare without a hard stop. |
| 3 | Educate your neurologists and immunologists now. Physicians ordering transfer factor for MS patients may not know this is categorically excluded under Medicare. A one-page summary of NCD 143 sent to your neurology and immunology departments prevents upstream ordering that creates downstream billing problems. This is a medical necessity conversation to have before a claim is ever generated. |
| 4 | Confirm private payer coverage separately. NCD 143 governs Medicare only. If you're billing commercial payers for transfer factor MS treatment, check each plan's coverage policy individually. Some commercial plans follow Medicare NCDs. Others don't. Don't assume this non-coverage applies across all payers — and don't assume commercial plans cover it just because Medicare doesn't. |
| 5 | Document patient notification for any affected cases. If a Medicare patient is pursuing transfer factor therapy for MS and intends to pay out of pocket, issue an Advance Beneficiary Notice of Noncoverage (ABN) before the service is provided. This is the one scenario where your billing team has a defined pathway. Without an ABN, you can't bill the patient for a Medicare-denied service. |
| 6 | Talk to your compliance officer if you've been billing this. If transfer factor for MS has appeared on Medicare claims from your practice, loop in your compliance officer before the March 7, 2026 effective date. Resubmission, refund obligations, and audit exposure are all on the table. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Transfer Factor Under NCD 143
The policy data for NCD 143 does not list specific CPT, HCPCS, or ICD-10 codes.
What That Means for Your Billing Team
No specific codes doesn't mean no exposure. It means CMS wrote this NCD as a categorical service-level exclusion rather than a code-level one. The non-coverage applies to the service — transfer factor administration for MS — regardless of how it's coded.
In practice, transfer factor may be billed under various infusion or immunotherapy codes depending on how it's administered. The absence of specific codes in NCD 143 means your billing team can't rely on a simple code-level scrub to catch these claims before submission. You need a clinical flag, not just a code flag.
Work with your coding team and your EHR vendor to identify how transfer factor administrations are currently documented and coded in your system. Then build a rule that routes any claim with an MS diagnosis and a transfer factor administration to manual review before Medicare submission.
No Covered Codes Under This Policy
| Code | Type | Description |
|---|---|---|
| None listed in NCD 143 | — | CMS does not designate any codes as covered for this service |
Not Covered / Experimental
| Service | Status | Reason |
|---|---|---|
| Transfer factor for multiple sclerosis treatment | Not Covered | Classified as experimental by CMS under NCD 143; no CPT or HCPCS codes specified |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.